Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ATCC licenses CRISPR/Cas9 technology from the Broad Institute
February 2016
SHARING OPTIONS:

ATCC
 
ATCC plans to use the gene-editing technology to develop a portfolio of new products and services to support basic and translational research.
The first ATCC product developed using the licensed technology is the EML4-ALK Fusion-A549 Isogenic Cell Line (ATCC CCL-185IG). The EML4-ALK Fusion mutation is critical for drug discovery and molecular diagnostics of non-small cell lung cancer. EML4-ALK Fusion-A549 Isogenic Cell Line has been intensively validated on the genomic, transcript and protein level, and is otherwise identical to the parental line. This isogenic cell line is more sensitive to ALK inhibitor crizotinib when compared to A549, and serves as a vital model to study cell signaling pathways in cancer as well as in drug screening.
 
ATCC

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.